Keytruda strength fuels earnings beat for Merck (MRK)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Merck (MRK) PT Raised to $127 at Morgan Stanley
January 30, 2024 10:52 AM ESTMorgan Stanley analyst Terrance Flynn raised the price target on Merck (NYSE: MRK) to $127.00 (from $116.00) while maintaining a Equalweight rating.... More



